592 related articles for article (PubMed ID: 16084449)
21. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
22. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
Kuźbicki L; Gajo B; Chwirot BW
Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.
Kuźbicki L; Aładowicz E; Chwirot BW
Melanoma Res; 2006 Oct; 16(5):435-44. PubMed ID: 17013093
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
26. Alpha-v-beta3 integrin expression in melanocytic nevi and cutaneous melanoma.
Neto DS; Pantaleão L; de Sá BC; Landman G
J Cutan Pathol; 2007 Nov; 34(11):851-6. PubMed ID: 17944725
[TBL] [Abstract][Full Text] [Related]
27. [Expression of galanin in melanocytic tumors].
Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
[TBL] [Abstract][Full Text] [Related]
28. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
29. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
Isabel Zhu Y; Fitzpatrick JE
J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
[TBL] [Abstract][Full Text] [Related]
30. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
31. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
32. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
33. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
34. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Patereli A; Stratigos A; Katsambas A
J Am Acad Dermatol; 2007 May; 56(5):815-24. PubMed ID: 17437889
[TBL] [Abstract][Full Text] [Related]
35. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression.
Lee C; Ramirez JA; Guitart J; Diaz LK
J Cutan Pathol; 2008 Nov; 35(11):989-94. PubMed ID: 18537861
[TBL] [Abstract][Full Text] [Related]
36. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
37. Oestrogen receptor-beta expression in melanocytic lesions.
Schmidt AN; Nanney LB; Boyd AS; King LE; Ellis DL
Exp Dermatol; 2006 Dec; 15(12):971-80. PubMed ID: 17083364
[TBL] [Abstract][Full Text] [Related]
38. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
39. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
40. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]